You are here
Award Data
The Award database is continually updated throughout the year. As a result, data for FY24 is not expected to be complete until March, 2025.
Download all SBIR.gov award data either with award abstracts (290MB)
or without award abstracts (65MB).
A data dictionary and additional information is located on the Data Resource Page. Files are refreshed monthly.
The SBIR.gov award data files now contain the required fields to calculate award timeliness for individual awards or for an agency or branch. Additional information on calculating award timeliness is available on the Data Resource Page.
-
RNA aptamers for rapid response to COVID-19 variants
SBC: DOTQUANT LLC Topic: CDCABSTRACT The COVID-19 pandemic caused by SARS-CoV-2 viruses has had an unprecedented disruptive global impact. Although vaccination has been expected to end the spread, the fast mutations have increased the breakthrough infection rates in the fully vaccinated population. RNA viruses are known to have very high rates of mutation and evolution. The high rate of mutation is correlated with virulence ...
SBIR Phase I 2023 Department of Health and Human ServicesCenters for Disease Control and Prevention -
Chromosomal aberration detection in FFPE tissue using proximity ligation sequencing
SBC: PHASE GENOMICS, INC. Topic: NCIABSTRACT The detection of chromosomal aberrations is a frontline diagnostic for the spectrum of blood neoplasms. Chromosomal aberrations, such as translocations, inversions, deletions and insertions, have been historically identified using cytogenetic methods or more recently through application of long read sequencing or optical mapping technologies. These methods have been less applicable in sol ...
SBIR Phase II 2023 Department of Health and Human ServicesNational Institutes of Health -
Dialysate regeneration system based on photo-electrochemical urea oxidation and reactive adsorption to enable portable hemodialysis
SBC: KULEANA TECHNOLOGY, INC. Topic: 400PROJECT SUMMARY/ ABSTRACT Currently in the US there are over 400,000 kidney patients on dialysis. The primary therapy mode is hemodialysis and is performed in a hospital or private clinic. Current dialysis therapy requires a large device that must be continuously connected to a reverse osmosis (RO) system. A single treatment will require over 150L of AAMI dialysate making portable device unattaina ...
STTR Phase I 2023 Department of Health and Human ServicesNational Institutes of Health -
Novel diagnostic biomarker reference standards for newborn screening of Mucopolysaccharidoses type I and II.
SBC: GELBCHEM, LLC Topic: NICHDProject Summary The goal of this project is to design and prepare diagnostic biomarker reference standards for the endogenous glycosaminoglycan (GAG) Mucopolysaccharidosis type I (MPS-I) and type II (MPS- II) biomarkers. MPS-I and MPS-II are lysosomal storage disorders (LSDs) which are listed on the Recommended Uniform Screening Panel (RUSP) in the United States and are included in global Newborn ...
STTR Phase I 2023 Department of Health and Human ServicesNational Institutes of Health -
Next Generation Gene-Gun Delivered DNA and RNA Immunotherapeutic Vaccines for Melanoma.
SBC: ORLANCE, INC Topic: NCIPROJECT SUMMARY Orlance has developed a next-generation Gene Gun (MACH-1 GG) that efficiently delivers DNA and RNA into epidermal cells, leading to robust immune responses. Sequencing of tumors from individual patients has led to the identification of personalized neoantigens that could be targeted with cancer vaccines. However, technologies that can effectively deliver these cancer neoantigens an ...
SBIR Phase I 2023 Department of Health and Human ServicesNational Institutes of Health -
Deep learning methods to accelerate discoveryof drugs targeting gene regulatory proteins
SBC: TALUS BIOSCIENCE INC Topic: 400SUMMARY To evaluate how a drug candidate affects cells, researchers often study how the abundance or behavior of a specific set of proteins is changed by treatment with each compound. However, it is not currently possible to test the effect of every possible drug compound (rt500,000) on every human protein (~20,000) in hundreds of different types of cells. Even the most advanced protein analysis s ...
SBIR Phase I 2023 Department of Health and Human ServicesNational Institutes of Health -
Modulation of Protein S-nitrosylation Signaling as a Potential Therapeutic Breakthrough in Rheumatoid Arthritis
SBC: GSNO THERAPEUTICS, INC. Topic: NIAMSPROJECT SUMMARY Rheumatoid arthritis (RA) is a prevalent autoimmune disease of the joints that involves autoimmunity, B and T cell infiltration, mitochondrial dysfunction, ECM degradation, oxidative stress and inflammation, that ultimately lead to cartilage destruction and bone reabsorption. Oxidative stress is a hallmark of RA: reactive oxygen species (ROS) inflict direct damage via the oxidation ...
SBIR Phase I 2023 Department of Health and Human ServicesNational Institutes of Health -
Selective CYP26 inhibitors for the oral treatment of recalcitrant nodular acne.
SBC: DERMAXON LLC Topic: NIAMSProject Summary / Abstract DermaXon's project goal is to develop efficacious, substrate-based, selective inhibitors of CYP26s, the enzymes responsible for the metabolism of all-trans retinoic acid (atRA) in the epidermis, as an oral treatment for severe recalcitrant acne. This approach will provide an improved acne therapeutic without the adverse effects associated with currently marketed retinoid ...
SBIR Phase I 2023 Department of Health and Human ServicesNational Institutes of Health -
Apto-Ankle: Passive, Compliant Ankle with Enhanced Energy Storage and Return in Gait
SBC: ORTHOCARE INNOVATIONS LLC Topic: NICHDPROJECT SUMMARY The Apto-Ankle project will create a novel low-cost, lightweight, unpowered passive compliant ankle that addresses the weaknesses of currently marketed hydraulic passive ankles by combining +/-10° of plantar and dorsiflexion with a gait dependent toe lock to provide energy storage and return, all without use of microprocessors or powered components. Appropriate for DMERC K-2 and K ...
SBIR Phase I 2023 Department of Health and Human ServicesNational Institutes of Health -
Development of an immunomodulating peptide as a therapy for osteosarcoma in canine and human
SBC: PHARMAIN CORPORATION Topic: 102Osteosarcoma (OSA) is the most common primary malignancy of bone in children and adolescents, accounting for approximately 5% of all childhood tumors (www.cancer.gov). Osteosarcoma occurs primarily in the long bones of the limbs, including most commonly the femur, tibia, and humerus1. The current standard of care therapy for human patients diagnosed with OSA includes multi-agent neoadjuvant chemot ...
SBIR Phase II 2023 Department of Health and Human ServicesNational Institutes of Health